RA Capital Management 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 81 US equity positions worth $8.8bn in its Q3 2024 13F filing. The largest position was ASND at 16.5% of the reported book, followed by PCVX and JANX. Against the Q2 2024 filing, it opened 5 new positions, added to 8 and reduced 7 among the top 50 holdings.
What did RA Capital Management own in Q3 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S - ADR | Healthcare | 16.5% | $1.4bn | 9,710,428 | -4% | reduced |
| 2 | PCVX VAXCYTE INC | Healthcare | 11.3% | $992.9m | 8,689,190 | 6% | added |
| 3 | JANX JANUX THERAPEUTICS INC | Healthcare | 4.7% | $416.4m | 9,165,652 | 0% | held |
| 4 | LEGN LEGEND BIOTECH CORP-ADR | Healthcare | 4.2% | $365.8m | 7,506,934 | 0% | held |
| 5 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.6% | $318.8m | 6,084,412 | 0% | held |
| 6 | CLYM CLIMB BIO INC | 3.3% | $294.6m | 31,419,267 | 0% | held | |
| 7 | AVIDITY BIOSCIENCES INC | 3.3% | $289.4m | 6,300,408 | 17% | added | |
| 8 | TYRA TYRA BIOSCIENCES INC | Healthcare | 2.8% | $244.9m | 10,416,609 | 0% | held |
| 9 | EVH EVOLENT HEALTH INC - A | Healthcare | 2.7% | $240.8m | 8,514,862 | 0% | held |
| 10 | EWTX EDGEWISE THERAPEUTICS INC | 2.7% | $237.8m | 8,909,091 | 0% | held | |
| 11 | BIIB BIOGEN INC | Healthcare | 2.6% | $229.6m | 1,184,456 | 21% | added |
| 12 | DYN DYNE THERAPEUTICS INC | Healthcare | 2.6% | $229.2m | 6,381,144 | 5% | added |
| 13 | RXST RXSIGHT INC | Healthcare | 2.2% | $193.6m | 3,916,825 | 6% | added |
| 14 | BCAX BICARA THERAPEUTICS INC | 2.0% | $177.2m | 6,955,993 | – | new | |
| 15 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 1.8% | $157.5m | 10,860,977 | 0% | held |
| 16 | ARCELLX INC | 1.8% | $154.6m | 1,851,479 | 15% | added | |
| 17 | ARTV ARTIVA BIOTHERAPEUTICS INC | 1.7% | $152.2m | 9,853,302 | – | new | |
| 18 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.7% | $149.3m | 18,202,009 | 0% | held |
| 19 | GERN GERON CORP | Healthcare | 1.7% | $146.6m | 32,285,755 | -30% | reduced |
| 20 | VRNA VERONA PHARMA PLC - ADR | 1.6% | $144.1m | 5,009,653 | -34% | reduced | |
| 21 | NEWAMSTERDAM PHARMA CO NV | 1.5% | $133.9m | 8,064,000 | 0% | held | |
| 22 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.3% | $115.2m | 1,961,863 | 0% | held |
| 23 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 1.2% | $109.7m | 7,871,721 | 0% | held | |
| 24 | 89BIO INC | 1.2% | $104.9m | 14,175,398 | 0% | held | |
| 25 | RXRX RECURSION PHARMACEUTICALS-A | Healthcare | 1.2% | $101.4m | 15,384,615 | 0% | held |
| 26 | LENZ LENZ THERAPEUTICS INC | Healthcare | 1.1% | $99.2m | 4,178,823 | 0% | held |
| 27 | PEPG PEPGEN INC | Healthcare | 1.0% | $91.4m | 10,689,545 | 0% | held |
| 28 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.0% | $89.9m | 1,000,000 | 0% | held |
| 29 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.9% | $83.2m | 1,896,772 | 0% | held |
| 30 | TOURMALINE BIO INC | 0.7% | $65.3m | 2,538,925 | 0% | held | |
| 31 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 0.7% | $63.9m | 2,333,000 | 0% | held |
| 32 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.7% | $58.7m | 4,850,984 | 0% | held |
| 33 | ACRV ACRIVON THERAPEUTICS INC | 0.7% | $58.4m | 8,340,508 | 0% | held | |
| 34 | ASTRIA THERAPEUTICS INC | 0.6% | $56.2m | 5,105,213 | 1% | added | |
| 35 | 4D MOLECULAR THERAPEUTICS IN | 0.6% | $55.1m | 5,098,211 | 0% | held | |
| 36 | CGON CG ONCOLOGY INC | Healthcare | 0.6% | $52.7m | 1,397,433 | 0% | held |
| 37 | BCYC BICYCLE THERAPEUTICS PLC-ADR | Healthcare | 0.6% | $51.0m | 2,253,000 | 0% | held |
| 38 | NKTX NKARTA INC | Healthcare | 0.6% | $48.8m | 10,805,129 | 0% | held |
| 39 | BIOA BIOAGE LABS INC | 0.5% | $46.0m | 2,210,589 | – | new | |
| 40 | GHRS GH RESEARCH PLC | 0.5% | $44.7m | 6,686,689 | 1% | added | |
| 41 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 0.5% | $43.8m | 761,955 | -38% | reduced |
| 42 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 0.5% | $42.7m | 1,347,252 | – | new |
| 43 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 0.4% | $39.6m | 6,045,351 | 0% | held |
| 44 | MBX MBX BIOSCIENCES INC | Healthcare | 0.4% | $39.3m | 1,511,334 | – | new |
| 45 | ABOS ACUMEN PHARMACEUTICALS INC | 0.4% | $37.0m | 14,932,063 | 0% | held | |
| 46 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.4% | $36.5m | 10,229,099 | -12% | reduced |
| 47 | ITEOS THERAPEUTICS INC | 0.4% | $32.5m | 3,184,711 | -9% | reduced | |
| 48 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.3% | $30.2m | 4,330,446 | 0% | held |
| 49 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.3% | $27.8m | 4,878,000 | 0% | held |
| 50 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.3% | $27.1m | 1,061,233 | -50% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.